Shay Capital LLC bought a new position in HealthEquity, Inc. (NASDAQ:HQY - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 5,700 shares of the company's stock, valued at approximately $547,000.
A number of other institutional investors have also recently modified their holdings of the stock. Royal Bank of Canada raised its holdings in HealthEquity by 10.6% in the 4th quarter. Royal Bank of Canada now owns 433,190 shares of the company's stock worth $41,563,000 after acquiring an additional 41,434 shares during the last quarter. ProShare Advisors LLC increased its holdings in shares of HealthEquity by 42.8% in the 4th quarter. ProShare Advisors LLC now owns 28,253 shares of the company's stock worth $2,711,000 after purchasing an additional 8,462 shares in the last quarter. Quantinno Capital Management LP purchased a new position in shares of HealthEquity in the fourth quarter worth $305,000. Man Group plc lifted its holdings in shares of HealthEquity by 2.7% during the fourth quarter. Man Group plc now owns 217,782 shares of the company's stock valued at $20,896,000 after purchasing an additional 5,685 shares in the last quarter. Finally, Nomura Holdings Inc. purchased a new stake in shares of HealthEquity during the fourth quarter valued at $1,110,000. 99.55% of the stock is owned by hedge funds and other institutional investors.
Insider Activity
In related news, Director Robert W. Selander sold 5,750 shares of the firm's stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $77.65, for a total value of $446,487.50. Following the completion of the sale, the director now directly owns 84,969 shares in the company, valued at $6,597,842.85. This trade represents a 6.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael Henry Fiore sold 8,881 shares of the company's stock in a transaction dated Friday, April 4th. The shares were sold at an average price of $78.26, for a total transaction of $695,027.06. Following the transaction, the executive vice president now owns 56,655 shares in the company, valued at $4,433,820.30. The trade was a 13.55% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.20% of the company's stock.
HealthEquity Price Performance
HealthEquity stock traded up $2.22 during midday trading on Thursday, reaching $101.02. 743,723 shares of the stock traded hands, compared to its average volume of 799,088. The stock has a market cap of $8.74 billion, a P/E ratio of 92.67, a PEG ratio of 1.60 and a beta of 0.45. The stock's fifty day moving average is $88.09 and its 200-day moving average is $97.24. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.51. HealthEquity, Inc. has a 12 month low of $65.01 and a 12 month high of $115.59.
Analyst Ratings Changes
A number of brokerages have recently commented on HQY. The Goldman Sachs Group reduced their price target on shares of HealthEquity from $107.00 to $94.00 and set a "neutral" rating for the company in a research note on Thursday, March 27th. Wells Fargo & Company lifted their target price on shares of HealthEquity from $110.00 to $125.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Royal Bank of Canada started coverage on HealthEquity in a report on Thursday. They set an "outperform" rating and a $112.00 price target on the stock. Barrington Research reaffirmed an "outperform" rating and issued a $112.00 price objective on shares of HealthEquity in a report on Friday, April 11th. Finally, KeyCorp reduced their price objective on HealthEquity from $110.00 to $100.00 and set an "overweight" rating for the company in a research report on Wednesday, April 16th. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, HealthEquity presently has a consensus rating of "Buy" and a consensus price target of $112.33.
Check Out Our Latest Research Report on HealthEquity
HealthEquity Company Profile
(
Free Report)
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Featured Stories
Before you consider HealthEquity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.
While HealthEquity currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
